🔬 Science
5h ago
FDA support advances biomarker for earlier, more precise Parkinson's clinical trials
Source ↗
👁 0
💬 0
The Critical Path Institute (C-Path) has published "Regulatory endorsement for the application of alpha-synuclein seed amplification assay (αSyn-SAA) as a susceptibility and risk biomarker for clinical trials targeting synucleinopathies" in the Journal of Parkinson's Disease, marking a significant milestone for its Critical Path for Parkinson's consortium. The findings detail scientific, regulatory and collaborative efforts culminating in a U.S. Food and Drug Administration (FDA) biomarker Lette
Comments (0)